PARP1 and colorectal cancer: In conclusion, this study suggests that p53 can augment pKAL-induced anticancer effect by activating p53-dependent signaling and inducing cleavage of PARP1 and lamin A/C in HCT116 human colorectal cancer cells, and that the combination therapy of p53 and pKAL may be one of the efficient non-toxic chemotherapeutic strategies for cancer treatment.